key: cord-0960241-xvufp36n authors: Khan, Luqman; Ul Khaliq, Nisar; Ullah, Asad; Rafiq, Naseem; Ullah, Mujib title: COVID-19 Pandemic: Mechanistic approaches and gender vulnerabilities date: 2020-11-25 journal: Saudi Pharm J DOI: 10.1016/j.jsps.2020.11.014 sha: 3fe5dc735e4130272144e91c47e32405b46844b3 doc_id: 960241 cord_uid: xvufp36n Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is highly pathogenic virus that results in coronavirus-19 disease (COVID-19) a severe respiratory damaging syndrome that causes serious complications for health worldwide. This novel virus and disorder were unfamiliar beforehand the epidemic started in Wuhan, China, in December 2019. COVID-19 is currently a pandemic influencing several countries worldwide. One of the mysteries of the new coronavirus is that it is deadlier for men than women as the mortality in males seems to be twice in every age group of females. Since its emergence in Wuhan, a city in Hubei province of China, COVID-19 has provoked high infectivity around the globe. According to Global Health 5050, a society that encourages genderspecific similarities in health care, (Sharma, Volgman, & Michos, 2020; Sohrabi et al., 2020) male populations infected with the 2019 novel coronavirus-19 are prone to more acute infections following deaths as compared to females (Xie, Tong, Guan, Du, & Qiu, 2020) . The report suggested a role of sex biology in humans' risk of infectivity and death as a consequence of COVID 19. CoV-19 attach to the body's defense cells (immune cells), triggering the antibody reaction in COVID 19-infected and non-symptomatic individuals. Typically, males produce fewer robust immune responses than females and are highly prone to a selection of contagious means (Conti & Younes, 2020; Klein & Flanagan, 2016) . Several reports propose variances between males and females in their immune reaction to communicable and inflammatory illnesses like TB, malaria, hepatitis, HIV-1, mumps, measles, flu, and so on (Rettew, Huet-Hudson, & Marriott, 2008) . Females are functional mosaics for X-lined genes that are related to immunity hence qualifying them to have stronger innate and adaptive immune responses and low infectivity (Fung, Huang, & Liu, 2014) . Structural changes in the host cells due to virus overload may also contribute to the high infectivity in male (Schurz et al., 2019) . A recent study has revealed the role gender plays in morbidity and mortality of SARS-CoV-2 infection (Drosten et al., 2003) . Studies pondering the mechanistic aspect for males' infectivity suggest that males have high concentration of circulating angiotensin-converting enzyme 2 (ACE2) than in their females counterpart (Patel, Velkoska, & Burrell, 2013; Ullah, 2020a) . ACE2 is the targeting receptor site for the (SARS-CoV) and the associated human respiratory coronavirus NL63, that exhibit in human airway epithelia and lung parenchyma (Jia et al., 2005) . High-throughput sequencing has shown that (SARS-CoV-2) look like (SARS-CoV) (Jia et al., 2005) . Similarly, severe acute respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus preferentially attack the (ACE2) receptors due to sequencing similarity. Hence, it is relatively rational that males are more likely to be affected by (SARS-CoV-2) in contrast to females. Researchers sequenced the genome of the virus and established numerous auspicious vaccine candidates for experimental tests (Grifoni et al., 2020) . The recovered antibodies from COVID-19 individuals might be considered to treat persons with initial signs and stop infection further (Casadevall & Pirofski; Jin et al., 2020; Wu et al., 2020) . The role of TMPRSS2 in coronavirus infections, and modulation of COVID-19 severity is still unknown (Cheng et al., 2015) . Some reports suggest its involvement in influenza severity in humans and animals (Cheng et al., 2015) . TMPRSS2 (testosterone regulated gene) is higher in men than women. However, TMPRSS2 expression levels and their role are also regulated by estrogen-dependent signaling (Cheng et al., 2015; Penna, Mercurio, Tocchetti, & Pagliaro, 2020; Sakai et al., 2015) . The higher mortality of COVID-19 in men may be due to sex-specific responses, as the immune cells obtained from women usually show a greater response compared to those isolated from men (Scotland, Stables, Madalli, Watson, & Gilroy, 2011) . Male has lower basal immunoglobulin levels and a smaller number of circulating and resident CD4/CD8 T-lymphocytes ratio than Females (Amadori et al., 1995; Li, Jerkic, Slutsky, & Zhang, 2020) . So far, no vaccine has been approved by the Food and Drug Administration (FDA) for COVID-19 treatment. However, some potential drugs have been reported which might help to reduce the severity of COVID-19. Upon intravenous or subcutaneous administration of Tocilizumab helps in reducing the mortality and as well as the risk of invasive mechanical ventilator in severe COVID-19 (Guaraldi et al., 2020) . Angiotensin receptor blockers (ARBs) have effects that are parallel to angiotensin converting enzyme (ACE) inhibitors, however ACE inhibitors act by inhibiting the development of angiotensin II instead of blocking the binding of angiotensin II to muscles on blood vessels (Jia et al., 2005; Ullah, 2020b) . ARBs are used for regulating high blood pressure, to treat heart failure, and restrain kidney failure in individuals with diabetes (Ullah, 2020a; Xie et al., 2020) . Hence, angiotensin receptor blockers (ARBs such as losartan, valsartan, telmisartan, etc.) can be a novel therapeutic approach to block the binding and therefore, attachment of SARS-CoV-2 RBD to ACE2-expressing cells, thus inhibiting their infection to the host cells. Apart from antivirals, immunotherapeutic strategies are suggested the role of the immune response as the host defense against the virus, and the fact that SARS-CoV-2 suppresses interferon induction as an immune evasion approach (Drosten et al., 2003; Ullah, 2020a) . Active immunization via vaccines, interferon administration, passive immunotherapy by convalescent plasma or synthesized monoclonal and polyclonal antibodies, as well as immunomodulatory drugs, are different immunotherapeutic approaches against the (SARS-CoV-2) (Owji, Negahdaripour, & Hajighahramani, 2020; Ullah, 2020b) . Some of these vaccines are in advanced human clinical trials. Convalescent plasma therapy is already exercised in several countries to help save the lives of severely ill patients (Sharun et al., 2020) . Diverse antibodies that target several phases of SARS-CoV-2 pathogenesis or the related immune responses are also suggested. To treat the cytokine storm, induced at a later stage of the disease in some patients, immune modulation through JAK inhibitors, corticosteroids, and other cognate classes are assessed (Owji et al., 2020) . The sex and gender discrepancies seen in COVID-19 vulnerability underline the need to comprehend the influence of sex and gender on prevalence and case mortality of the disease and to modify treatment conferring to sex and gender. Understanding from previous outbreaks and pandemics has shown the significance of integrating sex and gender evaluation into preparation and response efforts for health interventions. These differences may be due to known sex differences in genes, chromosomes, and hormones that lead to very different responses to many diseases, including COVID-19. There is a need to design a structure that can develop secure, efficient vaccines and antiviral medicines faster for such outbreaks. Our whole health maintenance procedure moves slowly compared to speedy pathogens, this might be partly technical, political, and investment barriers. Not Applicable. Not Applicable. The article and the sources used have been cited in the article. Genetic control of the CD4/CD8 T-cell ratio in humans posting date. The convalescent sera option for containing COVID-19 Sex-based differences in susceptibility to severe acute respiratory syndrome coronavirus infection Identification of TMPRSS2 as a susceptibility gene for severe 2009 pandemic A (H1N1) influenza and A (H7N9) influenza Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection Identification of a novel coronavirus in patients with severe acute respiratory syndrome Coronavirus-induced ER stress response and its involvement in regulation of coronavirus-host interactions A sequence homology and bioinformatic approach can predict candidate targets for immune responses to SARS-CoV-2 Tocilizumab in patients with severe COVID-19: a retrospective cohort study ACE2 receptor expression and severe acute respiratory syndrome coronavirus infection depend on differentiation of human airway epithelia Gender differences in patients with COVID-19: Focus on severity and mortality Sex differences in immune responses Molecular mechanisms of sex bias differences in COVID-19 mortality Immunotherapeutic approaches to curtail COVID-19 Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in? Sex-related differences in COVID-19 lethality Testosterone reduces macrophage expression in the mouse of toll-like receptor 4, a trigger for inflammation and innate immunity A mutant H3N2 influenza virus uses an alternative activation mechanism in TMPRSS2 knockout mice by loss of an oligosaccharide in the hemagglutinin stalk region The X chromosome and sex-specific effects in infectious disease susceptibility Sex differences in resident immune cell phenotype underlie more efficient acute inflammatory responses in female mice Sex differences in mortality from COVID-19 pandemic: are men vulnerable and women protected? Case Reports Antibody-based immunotherapeutics and use of convalescent plasma to counter COVID-19: advances and prospects World Health Organization declares global emergency: A review of the 2019 novel coronavirus (COVID-19) Novel Coronavirus (COVID-19) Treatment Options The Pandemic of Novel Coronavirus Disease 2019 (COVID-19): Need for an Immediate Action Genome composition and divergence of the novel coronavirus (2019-nCoV) originating in China Clinical characteristics of patients who died of coronavirus disease 2019 in China The authors declare no competing interests.